Earnings Call Summary | Neuraxis(NRXS.US) Q4 2023 Earnings Conference
Earnings Call Summary | Neuraxis(NRXS.US) Q4 2023 Earnings Conference
The following is a summary of the NeurAxis, Inc. (NRXS) Q4 2023 Earnings Call Transcript:
以下是神經軸公司（NRXS）2023年第四季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
NeurAxis experienced a decrease in revenues in fiscal year 2023 to $2.5 million, down 8.4% from the previous year, predominantly due to reduced shipments.
Q4 revenues saw a drop to $531.5 thousand compared to $613.1 thousand in Q4 2022.
Despite a reduction in selling expenses to $323.6 thousand from prior year's $410.9 thousand, the company's net loss heightened to $14.6 million in 2023, much higher than the $4.8 million loss in 2022.
The Q4 net loss stood at $5.3 million, mainly because of a $3.7 million debt extinguishment cost and higher G&A expenses.
The company's financial restatement for certain periods in 2023 resulted in an upshot of $3.7 million in the net loss and an equal increase to additional paid-in-capital.
NeurAxis在2023財年的收入下降至250萬美元，比上年下降8.4％，這主要是由於出貨量減少。
與2022年第四季度的613,100美元相比，第四季度的收入下降至531,500美元。
儘管銷售費用從去年的410,900美元減少至323,600美元，但該公司的淨虧損在2023年增加至1,460萬美元，遠高於2022年的480萬美元虧損。
第四季度的淨虧損爲530萬美元，這主要是由於370萬美元的債務清償成本和更高的併購費用。
該公司在2023年某些時期的財務重報使淨虧損達到370萬美元，而額外的實收資本也相應增加。
Business Progress:
業務進展：
The company treated 830 children using its IB-Stim technology in 2023, marking a penetration rate of 0.14%.
NeurAxis noted significant growth in insurance coverage and plans for further expansion in the following year.
Working towards acquiring a Category 1 billing code, the company already has a technology-specific one.
After securing $6.1 million in convertible financing, the company intends to commercialize additional devices like the RED, expecting its FDA clearance in the fall of 2024.
NeurAxis expects a rise in its revenues, powered by expanding insurance coverage and the launch of RED device, projecting a more profound growth wave into 2024 and 2025.
The company is strategically focusing on market education, wider insurance acceptance, and commercializing its RED technology to enable swift growth. The introduction of RED technology is anticipated to serve as a significant revenue driver. Despite a Q4 revenue dip, the company is diversifying its customer base and optimistically sees this as a move towards improved insurance coverage and reimbursement rates.
2023年，該公司使用其ib-STIM技術治療了830名兒童，普及率爲0.14％。
NeurAxis注意到保險覆蓋範圍顯著增長，並計劃在次年進一步擴張。
爲了獲得1類賬單代碼，該公司已經有了特定技術的賬單代碼。
在獲得610萬美元的可轉換融資後，該公司打算將RED等其他設備商業化，預計將在2024年秋季獲得美國食品藥品管理局的批准。
NeurAxis預計，在擴大保險範圍和推出RED設備的推動下，其收入將增加，預計到2024年和2025年將出現更深刻的增長浪潮。
該公司在戰略上將重點放在市場教育、擴大保險接受度以及將其RED技術商業化上，以實現快速增長。預計RED技術的引入將成爲重要的收入驅動力。儘管第四季度收入下降，但該公司仍在實現客戶群的多元化，並樂觀地認爲這是朝着改善保險覆蓋面和報銷率邁出的一步。
More details: Neuraxis IR
更多詳情： Neuraxis 紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。